Related Experiment Video
Updated: Nov 15, 2025
09:21
Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
11.7K
Development of a genomic predictive model for cholangiocarcinoma using copy number alteration data
Inês Tavares1, Ricardo Martins2,3,4,5, Ilda Patrícia Ribeiro1,2,5,6
1University of Coimbra, Cytogenetics and Genomics Laboratory, Institute of Cellular and Molecular Biology, Faculty of Medicine, Coimbra, Portugal.
Journal of Clinical Pathology
|March 2, 2021
Summary
This study characterized cholangiocarcinoma (CC) genomics, identifying distinct genomic alterations in intrahepatic (ICC) and extrahepatic (ECC) CC. A genomic model differentiated these subtypes with 71.43% accuracy, showing ECC patients had poorer survival.
Area of Science:
- Genomics
- Oncology
- Biliary tract diseases
Background:
- Cholangiocarcinoma (CC) is a rare biliary tract cancer with distinct intrahepatic (ICC) and extrahepatic (ECC) forms.
- Genomic characterization is crucial for understanding CC subtypes and developing targeted therapies.
Purpose of the Study:
- To perform a comprehensive genomic characterization of CC tumors.
- To develop a genomic model for differentiating ICC from ECC.
- To compare survival outcomes between ICC and ECC patients.
Main Methods:
- Array comparative genomic hybridization (aCGH) was used to analyze DNA from 23 CC tumor samples (10 ECC, 13 ICC).
- A support vector machine algorithm was applied to genomic data for ICC/ECC classification.
- Survival analysis was conducted to compare patient outcomes between ICC and ECC groups.
Main Results:
- Specific genomic alterations were identified for ICC (e.g., gain of Xp, loss of 3p) and ECC (e.g., gain of 16p25.3, loss of 3q26.1).
- A shared gain of 2q37.3 was observed in both ICC and ECC.
- The developed genomic model, using four chromosomal regions, distinguished ICC from ECC with 71.43% accuracy; ECC patients had an average survival 8 months shorter than ICC patients.
Conclusions:
- Genomic characterization provides insights into CC subtypes.
- A validated genomic model can aid in patient management and targeted therapy development for CC.
- Further validation of the genomic model in larger CC cohorts is warranted.
